Attovia Therapeutics, Inc.
NNASDAQ:ATTO14.50
USD
+0.32
(+2.26%)
CIK
2058707
ISIN
US04987L1026
CUSIP
04987L102
Return %
Stock
S&P 500
1Y
2,975.29
14.20
3Y
2,975.29
81.12
5Y
-46.63
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Tao Fu
- Full Time Employees
- 44
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 1091 Industrial Rd, Ste 310 San Carlos CA United States 94070
- IPO Date
- Aug 5, 2026
- CIK
- 0002058707
- Website
- attovia.com
- Similar Companies
- Business
- Atento S.A. (NYSE: ATTO) provides customer relationship management (CRM) and business process outsourcing (BPO) services, including sales, customer care, technical support, collections, back office, and business transformation outsourcing (BTO) augmented by artificial intelligence (AI), consulting, predictive analytics, and digital channels such as SMS, email, chats, social media, apps, and voice; it serves clients in telecommunications, financial services, consumer goods, retail, public administration, healthcare, travel, transportation, logistics, technology, and media sectors. The company operates primarily in Latin America, Brazil, the United States, Europe, the Middle East, and Africa, with approximately 127,000 employees. Founded in 1999 and headquartered in Luxembourg at 1 Rue Hildegard Von Bingen, Atento reinforces its strategic focus on Latin America and the United States through a November 2025 agreement to sell its Spanish operations to ABAI, enabling emphasis on AI-driven technologies, robotic process automation, and advanced analytics for customer experience transformation; it recently secured up to $30 million in additional liquidity in October 2025 and appointed Chris Condon as President and General Manager of its USNS region.